Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.

Nature nanotechnology - 1 Jul 2021

Li Ran, Ng Thomas S C, Wang Stephanie J, Prytyskach Mark, Rodell Christopher B, Mikula Hannes, Kohler Rainer H, Garlin Michelle A, Lauffenburger Douglas A, Parangi Sareh, Dinulescu Daniela M, Bardeesy Nabeel, Weissleder Ralph, Miller Miles A

Abstract excerpt

Nanoparticulate albumin bound paclitaxel (nab-paclitaxel, nab-PTX) is among the most widely prescribed nanomedicines in clinical use, yet it remains unclear how nanoformulation affects nab-PTX behaviour in the tumour microenvironment. Here, we quantified the biodistribution of the albumin carrier and its chemotherapeutic payload in optically cleared tumours of genetically engineered mouse models, and compared the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucose
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nanoparticles

Share to Neoplasms, Experimental

Share to Paclitaxel

Share to Pinocytosis

Share to RAW 264.7 Cells

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33958764
DOI: 10.1038/s41565-021-00897-1
PMCID: PMC8491539

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.PMID 33958764Read ↗

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read ↗

KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Semantic proximity Read ↗

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.Semantic proximity Read ↗

Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.Semantic proximity Read ↗

Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.Semantic proximity Read ↗

Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.Semantic proximity Read ↗

Nab-paclitaxel fused with the <i>de novo</i> designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacySemantic proximity Read ↗

RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.Semantic proximity Read ↗

Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin-Drug Conjugate Response.Semantic proximity Read ↗

Enhancing Cancer Therapy through Polymeric Nano-particles: Targeted Drug Delivery StrategiesSemantic proximity Read ↗

Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC.Semantic proximity Read ↗

Lipid Nanoparticle Delivery of Small Proteins for Potent In Vivo RAS InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.